Hematopoietic stem cell transplantation: A new therapy for autoimmune disease

Oncologist

Volumn 4, Issue 1, 1999, Pages 77-83

  Burt, Richard K ^a   Traynor, Ann E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033062015     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-1-77     Document Type: Review

References (54)

1. Oksenberg JR, Panzara MA, Begovich AB et al. Selection for T-cell Vβ-Dβ-Jβ gene rearrangements with specificity for myelin basic peptide in brain lesions of multiple sclerosis. Nature 1993;362:68-70.
2. Oksenberg JR, Stuart S, Begovich AB et al. Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients. Nature 1990;345:344-346.
3. Kotzin BL, Karuturi S, Chou YK et al. Preferential T-cell receptor β chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991;88:9161-9165.
4. Posnett DN, Schmelin I, Burton DA et al. T cell antigen receptor V gene usage. Increase in V beta 8+ T cells in Crohn's disease. J Clin Invest 1990;85:1770-1776.
5. Desai-Mehta A, Mao C, Rajagopalan S et al. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995;95:531-541.
6. Even J, Lim A, Puisieux I et al. T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor β-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases: Res Immunol 1995;146:65-80.
7. Holbrook MR, Tighe PJ, Powell RJ. Restrictions of T cell receptor b chain repertoire in the peripheral blood of patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:627-631.
8. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
9. Pincus T, Callahan LF. Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict long-term morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992;19:1051-1057.
10. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol 1994;23:21-30.
11. Jacobsson LT, Knowler WC, Pillemer S et al. A cross-sectional and longitudinal comparison of the Rome criteria for active rheumatoid arthritis (equivalent to the American College of Rheumatology 1958 criteria) and the American College of Rheumatology 1987 criteria for rheumatoid arthritis. Arthritis Rheum 1994;37:1479-1486.
12. Furst DE. Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 1994;20:309-319.
13. Corbett M, Dalton S, Young A et al. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-723.
14. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-494.
15. Myllykangas-Luosujarvi R, Aho K, Kautiainen H et al. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-153.
16. Bendtsen P, Bjurulf P, Trell E et al. Cross-sectional assessment and subgroup comparison of functional disability in patients with rheumatoid arthritis in a Swedish health-care district. Disabil Rehabil 1995;17:94-99.
17. Pincus T, Callahan LF. The "side effects" of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32:28-37.
18. Cheigh JS, Kim H, Stenzel KH et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990;16;189-195.
19. Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991;21:73-80.
20. Gladman DD. Prognosis of systemic lupus erythematosus and factors that affect it. Curr Opin Rheumatol 1992;4:681-687.
21. Choen MG, Li EK. Mortality in systemic lupus erythematosus: active disease is the most important factor. Aust NZ J Med 1992;22:5-8.
22. Austin HA III, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-391.
23. Abu-Shakra M, Urowitz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-1270.
24. Gladman DD. Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Current Opin Rheumatol 1993;5:587-595.
25. Gulko PS, Reveille JD, Koopman WJ et al. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993;20:1684-1693.
26. Drenkard C, Villa AR, Alarcon-Segovia D et al. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994;21:1067-1072.
27. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-429.
28. Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 1992;13:427-428.
29. + thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr, mice. Proc Natl Acad Sci USA 1993;90:10340-10344.
30. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
31. Lipton HL. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun 1975;11:1147-1155.
32. Lipton HL, Kratochvil J, Sethi P et al. Theiler's virus antigen detected in mouse spinal cord 2 1/2 years after infection. Neurology 1984;34:1117-1119.
33. Miller SD, Vanderlugt CL, Begolka WS et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997;3:1133-1136.
34. Rodriguez M, Patick AK, Pease LR. Abrogation of resistance to Theiler's virus-induced demyelination in C57BL mice by total body irradiation. J Neuroimmunol 1990;26:189-199.
35. Lipton HL, Dal Canto MC. Theiler's virus-induced demyelination: prevention by immunosuppression. Science 1976;192:62-64.
36. Marmont AM, van Bekkum DW. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transplant 1995;16:497-498.
37. Burt RK, Bums W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995;16:1-6.
38. Marmont AM, Tyndall A, Gratwohl A et al. Hematopoietic precursor stem cell transplantation for autoimmune diseases. Lancet 1995;345:978.
39. Burt RK. BMT for severe autoimmune diseases: an idea whose time has come. Oncology 1997;11:1001-1014, 1017.
40. Euler HH, Marmont AM, Bacigalupo A et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-3625.
41. Brodsky RA, Petri M, Smith BD et al. Immunoablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med 1998;129:1031-1035.
42. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high dose cyclophosphamide without bone marrow transplantation. Blood 1996;87:491-494.
43. Fassas A, Annagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631-638.
44. Burt RK, Traynor AE, Cohen B et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998;21:537-541.
45. Joske DJL, Ma DT, Langlands DR et al. Autologous bone-marrow transplantation for rheumatoid arthritis (Letter). Lancet 1997;350:337-338.
46. Burt RK, Traynor AE, Ramsey-Goldman R. Hematopoietic stem-cell transplantation for systemic lupus erythematosus (Letter). N Engl J Med 1997;337:1777-1778.
47. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation (Letter). Lancet 1997;349:254.
48. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-3514.
49. McSweeney PA, Furst DE, Storek J et al. High dose immuno-suppressive therapy (HDIT) using total body irradiation (TBI), cyclophosphamide (CY) and ATG with autologous CD34 selected peripheral blood stem cell (PSC) rescue as treatment for severe systemic sclerosis. Blood 1998;92:295a (abstract No. 1208).
50. Wulffraat NM, Vlieger A, Brinkman D et al. Autologous stem cell transplantation (ASCT) in refractory polyarticular and systemic JCA. Arthritis Rheum 1998;41:S131 (abstract No. 581).
51. Brooks PM, Snowden J, Biggs J et al. A pilot dose escalation of high dose cyclophosphamide (CY) and autologous stem cell therapy (ASCT) in active rheumatoid arthritis (RA). Arthritis Rheum 1998;41:S132 (abstract No. 598).
52. Burt RK, Pope R, Schroeder J et al. Hematopoietic stem cell transplantation of autoimmune disease. Arthritis Rheum 1998;41:S241 (abstract No. 1253).
53. Burt RK, Burns WH, Cohen B et al. T cell depleted autologous hematopoietic stem cell transplantation in patients with severe autoimmune diseases. Blood 1998;92:324a (abstract No. 1327).
54. + selected hematopoietic stem cell support for chronic refractory autoimmune thrombocytopenia. Blood 1998;92:178a (abstract No. 719).